Kairos Pharma Ltd. (NYSE American: KAPA) has been awarded the 2025 Clinical Trials Arena Excellence Award in the Research and Development category for Advanced Prostate Cancer. The award recognizes the company's work on ENV-105 (carotuximab), a first-in-class monoclonal antibody targeting CD105, which is being developed to address treatment resistance in metastatic castration-resistant prostate cancer (mCRPC). The accolade follows positive interim safety and efficacy results from a Phase 2 randomized clinical trial evaluating ENV-105 in combination with apalutamide.
CD105 is a protein identified as a key driver of resistance to various cancer treatments. Elevation of CD105 in response to standard therapy often leads to resistance and disease relapse. ENV-105 aims to reverse this drug resistance by targeting CD105 and restoring the effectiveness of standard therapies across multiple cancer types. The company's approach utilizes structural biology to overcome drug resistance and immune suppression in cancer, positioning it at the forefront of oncology therapeutics.
Currently, ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer, addressing significant unmet medical needs. The Clinical Trials Arena Excellence Awards highlight innovative clinical research, and Kairos Pharma's recognition underscores the potential impact of its therapy on patients with advanced prostate cancer who have limited treatment options.
For more details, visit the full press release at https://ibn.fm/jWi2c.
